Navigation Links
Generex Biotechnology Vaccine Strategy Presented at International,Conference in London

WORCESTER, MA - May 24, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT) announced today that Dr. Douglas Powell, Director of Immunobiology at its wholly-owned Antigen Express subsidiary, has presented Antigen's vaccine development strategy at an international conference in London, UK. The international meeting, "Developing New Anti-Infective Agents - Challenges and Opportunities" (www.anti-infectives-forum.com), is being held May 24th and 25th and brings together leading individuals from academia, industry, and regulatory agencies.

The focus of Dr. Powell's presentation was the immunogenicity of proprietary peptide vaccines being developed by Antigen Express, both when used alone and in combination with other types of vaccines. The Company is currently conducting a Phase II clinical trial of one of its peptides in breast cancer patients and a Phase I trial in volunteers of other peptides for the potentially pandemic H5N1 avian influenza. In both of these disease areas, cancer and avian influenza, novel forms of immunotherapy and vaccine are clearly needed.

About Generex


Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMistT device. The Company's flagship product, oral insulin (Generex Oral-lynT), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core p
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
11. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
Post Your Comments:
(Date:5/15/2008)...BRIDGEWATER, N.J., May 15 /...ounced today that findings from the,landmark ATHEN...l therapy,for the treatment of patients with atria...sk of cardiovascular hospitalizations or death fro...0.00000002), meeting the study,primary endpoint. T...
(Date:5/15/2008)...BOSTON, May 15 /- CenterWatch, a publ... market research about clinical,trials, finds that...e EDC,(electronic data capture) systems. More than... indicated that they had been trained on three or ...d that the effectiveness of,their EDC training had...
(Date:5/15/2008)...care Advantage Fee-For-Service Plan Positions Blue...iness, According to a New Report from ...enn., May 15 /- HealthLeaders-InterSt...ntelligence, reports that as the,economy continues...f,Michigan remains the best equipped of all of its...
(Date:5/15/2008)...GREEN BAY, Wis., May 15 /- Omega 3 fa...rther considered as a credible natural,alternative...ADHD patients,recent in vivo French study reveals...ffects of omega-3 in hyperactivity, French researc...e specific positive effects on,impulse control., ...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Congenital heart defects increasing among IVF twins 10631 1Congenital heart defects increasing among IVF twins 10631 2Max Nutrition Inc Completes Share Exchange with American Spring Pharmaceutical Inc 2906 1Max Nutrition Inc Completes Share Exchange with American Spring Pharmaceutical Inc 2906 2Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 1Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 2Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 3Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 4Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market 2904 1Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market 2904 2
...INNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-ye...III trial confirm the positive,clinical profile of...ring to nearly 1,300 the number of Endeavor patien...ficantly, among those 1,300,Endeavor patients, the...bosis using the independent, pre-specified clinica...
... Company Set to Host Evening Symposium at ATC -,...nced today that,an independent data monitoring c...data from the Phase 2b kidney transplant (PROMISE)...proximately 1/3 of,the anticipated 332 patients ... trial continue according to the original study,...
Other Medicine Technology:Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 3Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 2Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 3Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 4
(Date:5/16/2008)...R, Minn., May 16 /PRNewswire-USNewswire/ -- This r...Mayo Clinic in conjunction with the,National Cance...udy being presented at the American Society of Cli..., may change treatment practice,in about 25 percen...or,proposed changes to the way colorectal cancers ...
(Date:5/16/2008)... Covers More than 500 Workers, WASHINGTON, May 16...cs,and emergency medical technicians in the Greate...have ratified their first-ever contract as,Teamste...s are now covered by a,strong contract that gives ...," said Teamsters General President Jim Hoffa., T...
(Date:5/16/2008)...rom an international, multicenter Phase III clinic...therapy everolimus (RAD001) significantly delays c...ey cancer whose disease had worsened on other trea...n attending physician at Memorial Sloan-Kettering ...gs on May 31 at the annual meeting of the American...
(Date:5/16/2008)...n) Declaring that Primary care medicine is in a p...dent of the American College of Physicians (ACP), ...oyers and consumers to issue a call for comprehens... internists and other primary care physicians. ,...y care medicine in the U.S., Dr. Dale and other pa...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2
...revent, a powdered medication inhaled by asthma pa...us of an FDA Pulmonary-Allergy Drugs Advisory Comm...aths related to asthmatic symptoms in patients who...FDA documents released yesterday indicate that abo...
...ase III clinical trial of Ruboxistaurin (RBX) at a... inhibit Protein kinase C (PKC) – beta inhibitor, ...ith diabetes. The study was conducted in 252 pat...the Research team of Joslin Diabetes Centre across...
...e incidence of asthma, hay fever or any of the all...f brain cancer that may be fatal. Variations in ce...ore prone to the attacks of asthma and other aller...ns also prevent the incidence of the most common f...
... interesting study done in Nepal and India has sho...stoves is associated with increased risk of develo...ct has been found to be widely prevalent in develo... present study examined the association between co...
Other Medicine News:
This handheld reference is a practical guide to established surgical oncology principles for each organ system.
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan
The First Aid for the Surgery Clerkship is designed to prepare for the surgery clerkship examination and provides clinical diagnosis and treatment of many of the problems seen by surgeons.
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician.
Medicine Products: